# US 2023/0069055 A1 · Anti-pd-l1 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069055 A1
- Document ID: US20230069055A1
- Status: Published application
- Kind: A1
- Application number: 17/794,500
- Filed: 2021-01-21
- Published: 2023-03-02
- Earliest claimed: 2020-01-21
- Assignees: Bolt Biotherapeutics, Inc.
- Applicants: Bolt Biotherapeutics, Inc.
- Inventors: Michael N. ALONSO; David DORNAN; Karla HENNING; Justin KENKEL; Marcin KOWANETZ; Heidi LEBLANC; William MALLET
- Web page: https://patentgrep.com/patent/US20230069055A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.

## Claims

### Claim 1

A programmed death-ligand 1 (PD-L1) binding agent comprising an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide, wherein:
the immunoglobulin heavy chain variable region polypeptide comprises a complementarity determining region 1 (HCDR1) comprising any one of SEQ ID NOs: 1-14 and 167, a complementarity determining region 2 (HCDR2) comprising any one of SEQ ID NOs: 15-31, 168-173, and 203-206, and a complementarity determining region 3 (HCDR3) comprising any one of SEQ ID NOs: 32-52, 174-177, 207, and 208; or
the immunoglobulin light chain variable region polypeptide comprises a complementarity determining region 1 (LCDR1) comprising any one of SEQ ID NOs: 53-67 and 178-182, a complementarity determining region 2 (LCDR2) comprising any one of SEQ ID NOs: 68-79, and a complementarity determining region 3 (LCDR3) comprising any one of SEQ ID NOs: 80-91.

### Claim 2

A PD-L1 binding agent comprising an immunoglobulin heavy chain variable region of any one of SEQ ID NOs: 123-143, 184-193, and 209-213, or at least the complementarity determining regions (CDRs) thereof and an immunoglobulin light chain variable region of any one of SEQ ID NOs: 144-164 and 194-202 or at least the CDRs thereof.

### Claim 3

A PD-L1 binding agent comprising an immunoglobulin heavy chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 123-143, 184-193, and 209-213, and an immunoglobulin light chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 144-164 and 194-202.

### Claim 4 (depends on 1)

The PD-L1 binding agent of claim 1, which comprises the heavy and light chain immunoglobulin polypeptides, or at least the complementarity determining regions (CDRs) thereof, of a PD-L1 binding agent of Table 1.

### Claim 5 (depends on 1)

The PD-L1 binding agent of claim 1, wherein the binding agent is an antibody, an antibody conjugate, or an antigen-binding fragment thereof.

### Claim 6 (depends on 5)

The PD-L1 binding agent of claim 5, wherein the binding agent is an antibody fragment selected from F(ab′)2, Fab′, Fab, Fv, scFv, dsFv, dAb, and a single chain binding polypeptide.

### Claim 7 (depends on 5)

The PD-L1 binding agent of claim 5, wherein the binding agent is an antibody.

### Claim 8 (depends on 1)

The PD-L1 binding agent of claim 1, further comprising an immunoglobulin Fc region.

### Claim 9 (depends on 8)

The PD-L1 binding agent of claim 8, further comprising a transforming growth factor beta 1 (TGFβ1) receptor, or a fragment thereof that binds TGFβ1, attached to the Fc region.

### Claim 10 (depends on 7)

The PD-L1 binding agent of claim 7, wherein the antibody is an IgG, IgM, IgA, IgD, or IgE antibody.

### Claim 11 (depends on 7)

The PD-L1 binding agent of claim 7, wherein the antibody is an IgG antibody.

### Claim 12 (depends on 7)

The PD-L1 binding agent of claim 7, wherein the antibody exhibits antibody dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement dependent cytotoxicity (CDC).

### Claim 13 (depends on 1)

The PD-L1 binding agent of claim 1, wherein the binding agent is part of a bispecific antibody, chimeric antigen receptor, chimeric T cell receptor, or bispecific T-cell engager.

### Claim 14 (depends on 1)

A nucleic acid encoding the heavy chain immunoglobulin polypeptide of the anti-PD-L1 binding agent of claim 1.

### Claim 15 (depends on 1)

A nucleic acid encoding the light chain immunoglobulin polypeptide of the anti-PD-L1 binding agent of claim 1.

### Claim 16 (depends on 1)

A nucleic acid encoding the heavy chain immunoglobulin polypeptide and the light chain immunoglobulin polypeptide of the PD-L1 binding agent of claim 1.

### Claim 17 (depends on 1)

A vector comprising the nucleic acid sequence encoding the heavy and/or light chains of the anti-PD-L1 binding agent of claim 1.

### Claim 18 (depends on 1)

An isolated cell comprising the nucleic acid encoding the heavy and/or light chains of the anti-PD-L1 binding agent of claim 1, optionally in a vector.

### Claim 19 (depends on 1)

A method of providing a PD-L1 binding agent of claim 1, the method comprising expressing in a cell in vitro one or more nucleic acids encoding the immunoglobulin heavy and light chain polypeptides thereof.

### Claim 20 (depends on 1)

A composition comprising the PD-L1 binding agent of claim 1 or a nucleic acid encoding the heavy and/or light chains of same, optionally in a vector, and a pharmaceutically acceptable carrier.

### Claim at position 21

-24. (canceled)

### Claim 25 (depends on 1)

A method for treating a disease, disorder, or condition in a mammal that is responsive to PD-L1 inhibition or binding, the method comprising administering the PD-L1 binding agent of claim 1 or conjugate comprising same, or a composition comprising the PD-L1 binding agent or conjugate comprising same, to the mammal.

### Claim 26 (depends on 25)

The method of claim 25, wherein the disease, disorder, or condition is cancer.

### Claim 27 (depends on 25)

The method of claim 25, wherein the disease, disorder, or condition is an autoimmune disorder.

### Claim 28 (depends on 25)

The method of claim 25, wherein the disease, disorder, or condition is an infection.

### Claim 29 (depends on 1)

A method for enhancing or inhibiting an immune response in a mammal comprising administering the PD-L1 binding agent of claim 1 or conjugate comprising same, or a composition comprising the PD-L1 binding agent or conjugate comprising same, to the mammal.

### Claim 30 (depends on 29)

The method of claim 29, wherein the immune response is an anti-cancer immune response.

### Claim 31 (depends on 1)

A method of delivering a payload to a cell expressing PD-L1, the method comprising administering to the cell, or a mammal comprising the cell, a conjugate comprising a PD-L1 binding agent of claim 1 and a payload to the mammal.

### Claim 32 (depends on 1)

A hybridoma or cell line that expresses a PD-L1 binding agent of claim 1.
